Biblio

Export 3139 results:
[ Author(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
R. V. Bhat, Andersson, U., Andersson, S., Knerr, L., Bauer, U., and Sundgren-Andersson, A. K., “The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning?”, J Alzheimers Dis, vol. 64, no. s1, pp. S547-S554, 2018.
H. Bielarczyk, Jankowska-Kulawy, A., Hofling, C., Ronowska, A., Gul-Hinc, S., Rossner, S., Schliebs, R., Pawelczyk, T., and Szutowicz, A., “AβPP-Transgenic 2576 Mice Mimic Cell Type-Specific Aspects of Acetyl-CoA-Linked Metabolic Deficits in Alzheimer's Disease.”, J Alzheimers Dis, 2015.
G. Biella, Fusco, F., Nardo, E., Bernocchi, O., Colombo, A., Lichtenthaler, S. F., Forloni, G., and Albani, D., “Sirtuin 2 Inhibition Improves Cognitive Performance and Acts on Amyloid-β Protein Precursor Processing in Two Alzheimer's Disease Mouse Models.”, J Alzheimers Dis, vol. 53, no. 3, pp. 1193-207, 2016.
N. Bier, Belchior, Pda Cunha, Paquette, G., Beauchemin, É., Lacasse-Champagne, A., Messier, C., Pellerin, M. - L., Petit, M., Mioshi, E., and Bottari, C., “The Instrumental Activity of Daily Living Profile in Aging: A Feasibility Study.”, J Alzheimers Dis, vol. 52, no. 4, pp. 1361-71, 2016.
M. Bilgel, Koscik, R. L., An, Y., Prince, J. L., Resnick, S. M., Johnson, S. C., and Jedynak, B. M., “Temporal Order of Alzheimer's Disease-Related Cognitive Marker Changes in BLSA and WRAP Longitudinal Studies.”, J Alzheimers Dis, vol. 59, no. 4, pp. 1335-1347, 2017.
J. Bin Bae, Han, J. Won, Kwak, K. Phil, Kim, B. Jo, Kim, S. Gyeom, Kim, J. Lan, Kim, T. Hui, Ryu, S. - H., Moon, S. Woo, Park, J. Hyuk, Youn, J. Chul, Lee, D. Young, Lee, D. Woo, Lee, S. Bum, Lee, J. Jae, Jhoo, J. Hyeong, and Kim, K. Woong, “Impact of Mild Cognitive Impairment on Mortality and Cause of Death in the Elderly.”, J Alzheimers Dis, vol. 64, no. 2, pp. 607-616, 2018.
B. K. Binukumar, Pelech, S. L., Sutter, C., Shukla, V., Amin, N. D., Grant, P., Bhaskar, M., Skuntz, S., Steiner, J., and Pant, H. C., “Profiling of p5, a 24 Amino Acid Inhibitory Peptide Derived from the CDK5 Activator, p35 CDKR1 Against 70 Protein Kinases.”, J Alzheimers Dis, vol. 54, no. 2, pp. 525-33, 2016.
B. K. Binukumar, Shukla, V., Amin, N. D., Bhaskar, M., Skuntz, S., Steiner, J., Winkler, D., Pelech, S. L., and Pant, H. C., “Analysis of the Inhibitory Elements in the p5 Peptide Fragment of the CDK5 Activator, p35, CDKR1 Protein.”, J Alzheimers Dis, 2015.
C. Birkenbihl, Westwood, S., Shi, L., Nevado-Holgado, A., Westman, E., Lovestone, S., and Hofmann-Apitius, M., “ANMerge: A Comprehensive and Accessible Alzheimer's Disease Patient-Level Dataset.”, J Alzheimers Dis, vol. 79, no. 1, pp. 423-431, 2021.
M. Bisbe, Fuente-Vidal, A., López, E., Moreno, M., Naya, M., de Benetti, C., Milà, R., Bruna, O., Boada, M., and Alegret, M., “Comparative Cognitive Effects of Choreographed Exercise and Multimodal Physical Therapy in Older Adults with Amnestic Mild Cognitive Impairment: Randomized Clinical Trial.”, J Alzheimers Dis, vol. 73, no. 2, pp. 769-783, 2020.
R. Biswas, Kawas, C., Montine, T. J., Bukhari, S. A., Jiang, L., and Corrada, M. M., “Superior Global Cognition in Oldest-Old Is Associated with Resistance to Neurodegenerative Pathologies: Results from The 90+ Study.”, J Alzheimers Dis, vol. 93, no. 2, pp. 561-575., 2023.
A. Bittar, Al-Lahham, R., Bhatt, N., Moore, K., Montalbano, M., Jerez, C., Fung, L., McAllen, S., Ellsworth, A., and Kayed, R., “Passive Immunotherapy Targeting Tau Oligomeric Strains Reverses Tauopathy Phenotypes in Aged Human-Tau Mice in a Mouse Model-Specific Manner.”, J Alzheimers Dis, vol. 90, no. 3, pp. 1103-1122, 2022.
M. Bjerke, Kern, S., Blennow, K., Zetterberg, H., Waern, M., Börjesson-Hanson, A., Östling, S., Kern, J., and Skoog, I., “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
M. Bjerke and Engelborghs, S., “Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis.”, J Alzheimers Dis, vol. 62, no. 3, pp. 1199-1209, 2018.
C. M. Black, Fillit, H., Xie, L., Hu, X., M Kariburyo, F., Ambegaonkar, B. M., Baser, O., Yuce, H., and Khandker, R. K., “Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 185-193, 2018.
J. Blautzik, Kotz, S., Brendel, M., Sauerbeck, J., Vettermann, F., Winter, Y., Bartenstein, P., Ishii, K., and Rominger, A., “Relationship Between Body Mass Index, ApoE4 Status, and PET-Based Amyloid and Neurodegeneration Markers in Amyloid-Positive Subjects with Normal Cognition or Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 65, no. 3, pp. 781-791, 2018.
K. Blennow and Zetterberg, H., “The Past and the Future of Alzheimer's Disease Fluid Biomarkers.”, J Alzheimers Dis, vol. 62, no. 3, pp. 1125-1140, 2018.
K. Bloch, Gil-Ad, I., Vanichkin, A., Hornfeld, S. Henry, Koroukhov, N., Taler, M., Vardi, P., and Weizman, A., “Intracerebroventricular Streptozotocin Induces Obesity and Dementia in Lewis Rats.”, J Alzheimers Dis, vol. 60, no. 1, pp. 121-136, 2017.
K. Bloch, Gil-Ad, I., Vanichkin, A., Hornfeld, S. Henry, Taler, M., Dar, S., Azarov, D., Vardi, P., and Weizman, A., “Intracranial Transplantation of Pancreatic Islets Attenuates Cognitive and Peripheral Metabolic Dysfunctions in a Rat Model of Sporadic Alzheimer's Disease.”, J Alzheimers Dis, vol. 65, no. 4, pp. 1445-1458, 2018.
I. Blockx, Einstein, S., Guns, P. - J., Van Audekerke, J., Guglielmetti, C., Zago, W., Roose, D., Verhoye, M., Van der Linden, A., and Bard, F., “Monitoring Blood-Brain Barrier Integrity Following Amyloid-β Immunotherapy Using Gadolinium-Enhanced MRI in a PDAPP Mouse Model.”, J Alzheimers Dis, vol. 54, no. 2, pp. 723-35, 2016.
V. Bloniecki, Aarsland, D., Blennow, K., Cummings, J., Falahati, F., Winblad, B., and Freund-Levi, Y., “Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 57, no. 2, pp. 387-393, 2017.
E. R. Blonz, “Alzheimer's Disease as the Product of a Progressive Energy Deficiency Syndrome in the Central Nervous System: The Neuroenergetic Hypothesis.”, J Alzheimers Dis, vol. 60, no. 4, pp. 1223-1229, 2017.
J. Krzysztof Blusztajn, Aytan, N., Rajendiran, T., Mellott, T. J., Soni, T., Burant, C. F., Serrano, G. E., Beach, T. G., Lin, H., and Stein, T. D., “Cerebral Gray and White Matter Monogalactosyl Diglyceride Levels Rise with the Progression of Alzheimer's Disease.”, J Alzheimers Dis, vol. 95, no. 4, pp. 1623-1634, 2023.
M. Boada, Santos-Santos, M. A., Rodríguez-Gómez, O., Alegret, M., Cañabate, P., Lafuente, A., Abdelnour, C., Buendia, M., de Dios, M. José, Morera, A., Sanabria, Á., Campo, L., Ruiz, A., and Tárraga, L., “Patient Engagement: The Fundació ACE Framework for Improving Recruitment and Retention in Alzheimer's Disease Research.”, J Alzheimers Dis, vol. 62, no. 3, pp. 1079-1090, 2018.
M. Boada, Anaya, F., Ortiz, P., Olazarán, J., Shua-Haim, J. R., Obisesan, T. O., Hernandez, I., Muñoz, J., Buendia, M., Alegret, M., Lafuente, A., Tárraga, L., Núñez, L., Torres, M., Grifols, J. Ramon, Ferrer, I., Lopez, O. L., and Páez, A., “Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial.”, J Alzheimers Dis, vol. 56, no. 1, pp. 129-143, 2017.

Pages